51 – 60 of 69
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-Expressing platinum-resistant ovarian Cancer (PENELOPE)
(
- Contribution to journal › Article
-
Mark
Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer
(
- Contribution to journal › Article
-
Mark
Gain of 1q as a prognostic biomarker in Wilms Tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 trial : A SIOP renal tumours biology consortium study
(
- Contribution to journal › Article
- 2015
-
Mark
Evolution of Treatments for Peritoneal Metastases From Colorectal Cancer
2015) In Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33(18). p.2122-2123(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Computer automated bone scan index (BSI) as an analytically validated imaging biomarker to quantitate change in bone scan of patients with metastatic prostate cancer
2015) American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium In Journal of Clinical Oncology 33(15 Suppl). p.5044-5044(
- Contribution to journal › Published meeting abstract
-
Mark
Quantitative imaging by automated bone scan index (BSI) as a response biomarker in standard clinical care of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide
2015) American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium In Journal of Clinical Oncology 33(7 Suppl). p.288-288(
- Contribution to journal › Published meeting abstract
- 2014
-
Mark
Development of novel metastatic prostate cancer cell lines by “organoid” in vitro culture technology.
(
- Contribution to journal › Article
- 2011
-
Mark
Gemcitabine Plus Docetaxel Versus Docetaxel in Patients With Predominantly Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer: A Randomized, Phase III Study by the Danish Breast Cancer Cooperative Group
(
- Contribution to journal › Article
- 2010
-
Mark
Parametric Response Map as a Potential Imaging biomarker for Distinguishing Progression fromPseudo-progression in High Grade gliomas.
(
- Contribution to journal › Article
-
Mark
Finasteride to prevent prostate cancer : Should all men or only a high-risk subgroup be treated?
(
- Contribution to journal › Article